Nippon India Mutual Fund

Nippon India Nifty Pharma ETF-Growth

Equity: Sectoral-Pharma - Growth (Open ended)Download Report
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: NIFTY Pharma Total Return IndexCheck Portfolio Overlap →
₹29.08+0.05%
20 Nov 2026

Similar ETFs

Side-by-side comparison of Nippon India Nifty Pharma ETF-Growth with similar ETFs — tracking error, returns, AUM and expense ratio.
PeriodThis FundCategory AvgCategory Rank
1Y Return+25.57%19.81%5 / 29
3Y Return+22.02%21.01%5 / 19
5Y Return+16.60%15.94%4 / 15
10Y Return—14.83%—

Trailing annualised returns (%). Category rank: lower is better. Green = top third of category.

Please login to continue

ETFs in Equity: Sectoral-Pharma

Top ETFs by AUM in the Equity: Sectoral-Pharma category — see how Nippon India Nifty Pharma ETF-Growth compares on size and returns.

ETFs Tracking NIFTY Pharma Total Return Index

Top ETFs tracking the NIFTY Pharma Total Return Index — sorted by AUM to show the largest options available.

Frequently Asked Questions

Which ETFs are similar to Nippon India Nifty Pharma ETF-Growth?
ETFs similar to Nippon India Nifty Pharma ETF-Growth in the Equity: Sectoral-Pharma category include ICICI Prudential Nifty Healthcare ETF-Growth, Groww BSE Hospitals ETF-Growth, and Aditya Birla Sun Life Nifty Healthcare ETF-Growth. These ETFs follow a comparable investment mandate and are benchmarked against similar indices. You can compare them in detail — across returns, risk metrics, expense ratio, and portfolio composition — using the ETF comparison tool on sharpely.
What is the rank of Nippon India Nifty Pharma ETF-Growth in its category?
On a 3-year return basis Nippon India Nifty Pharma ETF-Growth is ranked 5 out of 19 ETFs in the Equity: Sectoral-Pharma category as of 19 Nov 2026. On a 5-year return basis it ranks 4 out of 15. Consistently ranking in the top across multiple time periods is a stronger signal of ETF quality than a single-period rank.
How does Nippon India Nifty Pharma ETF-Growth's expense ratio compare to similar ETFs?
Nippon India Nifty Pharma ETF-Growth has an expense ratio of 0.23%. The peers ICICI Prudential Nifty Healthcare ETF-Growth has an expense ratio of 0.18% and Groww BSE Hospitals ETF-Growth has 0.55%. Over the long term, a higher expense ratio can meaningfully drag on returns, so it is worth evaluating whether the ETF's performance justifies the additional cost.
How does Nippon India Nifty Pharma ETF-Growth's AUM compare to similar ETFs?
Nippon India Nifty Pharma ETF-Growth has an AUM of ₹1,756.56 crore. The peers ICICI Prudential Nifty Healthcare ETF-Growth has an AUM of ₹240.11 crore and Groww BSE Hospitals ETF-Growth has ₹184.45 crore. A large AUM can sometimes limit a ETF's ability to take meaningful positions in mid and small-cap stocks, as larger trades can move prices. This is particularly relevant for ETFs that invest outside large caps.
Which ETF has the best 3-year returns in the Equity: Sectoral-Pharma?
The top performing ETF in the Equity: Sectoral-Pharma category on a 3-year basis is Motilal Oswal BSE Healthcare ETF-Growth with a CAGR of 21.96% as of 19 Nov 2026. Nippon India Nifty Pharma ETF-Growth has delivered 22.02% CAGR over the same period, ranking 5 out of 19 ETFs. You can view and compare the full category ranking on sharpely.
How does Nippon India Nifty Pharma ETF-Growth rank in risk-adjusted returns vs peers?
On a risk-adjusted basis, Nippon India Nifty Pharma ETF-Growth has a Sharpe ratio of 1.06 compared to the Equity: Sectoral-Pharma average of 0.98 as of 19 Nov 2026. It ranks 1 out of 5 ETFs in its category on Sharpe ratio.